top of page

Global Digital Healthcare
Leader in Thyroidology

Through many years of robust clinical research,

THYROSCOPE has developed the world's first and only thyroid medical AI solution,

delivering the medical value of digital health technology.

THYROSCOPE is collaborating with global research institutions worldwide to establish a new standard in medical diagnosis through AI solutions.

Global Research

3locations

1location

37locations

1location

2locations

5locations

2locations

Main_Concact

Collaboration with THYROSCOPE

We are looking for researchers
who are passionate in innovating
with novel medical AI technology.

A new world shaped by
the innovation of Glandy

Product Portfolio

Eye icon

​Thyroid Eye Disease (TED)

Thyroid icon

Thyroid Dysfunction (TDF)

Product Pipeline
Discovery (1850 x 1600 px) (1).jpg
제목을-입력해주세요_-002 (6).jpg
5.png
Medical device approvals and certifications
  • Glandy CAS approved and designated as an innovative medical device by the MFDS (KFDA)
  • Medical device quality certification (EN ISO 13485:2016)
7.png
Global developments
  • First Korean company to be selected as a South Summit 100 Finalist
  • Submitted FDA De Novo application
6.png
Research achievements and conference presentations
  • Presented 5 times at the American Thyroid Association (ATA)
  • Glandy HYPER's medical device clinical trial protocol approved
8.png
Investments and fundraising
  • Raised 7.3 billion KRW (~5.2 million USD) in investments
  • 40 R&D government grants and support projects, totalling 8.8 billion KRW (~6.3 million USD)

History

2024

  • Submitted FDA De Novo application

  • Completed Series A funding with 4 billion KRW (~2.9 million USD)

  • Secured additional 4.7 billion KRW (~3.4 million USD) through government support projects

  • Glandy CAS, EXO, and Glandoc approved as medical devices

  • "Best Oral Award" at the 2024 Seoul International Congress of Endocrinology and Metabolism (SICEM)

  • Presentations at domestic and international conferences (e.g. ATA and ASOPRS) and publication of 2 SCI papers

  • Selected for Samsung Electronic C-Lab Outside program

  • 3 oral presentations at the American Thyroid Association (ATA)

  • "Healthcare Award" in the "Digital Therapeutics" category at the 10th Korea Leading Company Awards 2024

  • Research paper published in the Thyroid journal

  • 2 oral presentations and 1 poster presentation at the Korean Thyroid Association

  • Established German branch

2023

  • Obtained EN ISO 13485:2016 (Medical Device Quality Management System) certification

  • Selected for Techcrunch Startup Battlefield 200

  • 1 oral presentation, 1 highlight presentation, and 1 poster presentation at the American Thyroid Association (ATA)

  • First Korean company to be selected as a South Summit 100 Finalist

  • Received additional investments during Pre-Series A round

  • Glandy HYPER's medical device clinical trial protocol approved by the MFDS (KFDA)

2022
2021

  • Established US subsidiary

  • Obtained a Good Manufacturing Practice (GMP) certificate for medical device manufacturing and quality management standards compliance

  • 3rd place at the FLY ASIA Awards

  • Received the "Best Paper Award" at the Korean Thyroid Association

  • Abstract presentation at the American Thyroid Association (ATA)

  • Semi-finalist at SLUSH 2021

bottom of page